Prior histone deacetylase (HDAC), deacetylase (DAC), heat shock protein (HSP) inhibitors or valproic acid for the treatment of cancer is allowed
Prior anti-cancer treatment with MLN (ixazomib), histone deacetylase (HDAC), deacetylase (DAC), heat shock protein (HSP) inhibitors or valproic acid
Prior histone deacetylases (HDAC) inhibitor, deacetylase (DAC) inhibitor, heat shock protein (Hsp) inhibitor or valproic acid for the treatment of cancer
Prior histone deacetylase (HDAC), deacetylase (DAC), heat shock protein  (HSP) inhibitors or valproic acid for the treatment of cancer
Prior HDAC, deacetylase (DAC), heat shock protein (HSP) inhibitors or valproic acid for treatment of cancer
Prior therapy with a known heat shock protein  (HSP) inhibitor
RECURRENT/ PROGRESSIVE DIPG (STRATUM ): Patients have had prior histone deacetylase (HDAC), deacetylase (DAC), heat shock protein  (HSP) inhibitors for the treatment of their DIPG
Prior histone deacetylases (HDAC), deacetylase (DAC), heat shock protein  (HSP) inhibitors or valproic acid for the treatment of cancer
Patients must not have had any prior exposure to heat shock protein  (HSP) inhibitors (such as IPI- or ganetespib) or non-crizotinib ALK inhibitors (such as AP or LDK)
Prior therapy with heat shock protein (HSP)- inhibitors
Histone deacetylase (HDAC), deacetylase (DAC), heat shock protein (HSP) inhibitors or valproic acid for the treatment of cancer within  days; only Food and Drug Administration (FDA) approved drug are vorinostat and romidepsin the rest are considered investigational and are not allowed